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Estrus is that period of the reproductive
cycle in mammalian females in which ovu-
lation occurs and the female is typically
most receptive to mating. In rodents, the
most commonly used laboratory model for
studies of reproduction, estrus follows the
surge ofestrogen produced by the maturing
ovarian follicles during proestrus. Thus,
chemicals that induce estrus, or a biological
response associated with estrus, are tradi-
tionally defined as estrogens (1). The capac-
ity of a substance to induce such effects is
termed estrogenicity.
With growing concern that estrogenic
chemicals in the environment, either natu-
rally occurring or man-made, may adversely
affect the health ofhumans, domestic ani-
mals, and wildlife (2,3), the need for mean-
ingful, standardized, and widely accepted
methods for reliably detecting and charac-
terizing estrogenic chemicals has gained
importance. Many assays for estrogenicity
have been proposed and several are in
broad use. Descriptions of many of these
are found in the proceedings ofthe confer-
ence on Estrogens in the Environment, III:
Global Health Implications (4).
Because ofthe multiple biological effects
ofestrogens and the influence ofabsorption,
metabolism, distribution, and excretion on
the manifestation oftheir estrogenic activi-
ty, any single assay can provide only limited
information on those effects. In vitro assays
can provide valuable insights on mecha-
nisms of action but are restricted in their
capacity to mimicwhole animal metabolism
and distribution. In vivo assays permit the
detection of effects resulting from multiple
mechanisms but maygive indications only of
gross effects and reveal little about mecha-
nisms ofactivity.
In an initial effort to assess the utility of
using a combination of in vitro and in vivo
assays to screen for estrogenicity, 10 known
or alleged estrogenic chemicals were tested
using assays that assess estrogenic activity at
threedifferentlevels ofaction. The first assay,
competitive binding with the estrogen recep-
tor (ER), uses a cell-free system to determine
the extent towhich the testchemical binds to
the ER, as reflected by its effect on the bind-
ing of170-estradiol (5). Second, ifa chemi-
cal is estrogenic, the consequence ofits bind-
ing to the ER should be transcriptional acti-
vation of estrogen responsive genes. This
effect has been determined using an assay
that employs human HeLa cells transfected
with an ERand an estrogen response element
(ERE) linked to a chloramphenicol acetyl
transferase (CAT) reporter gene. Transcrip-
tional activation is determined by measuring
the amount ofCAT protein produced by the
cells following treatmentwith the test chemi-
cal (6). The third assay was used to deter-
mine effects on an estrogen-responsive tissue
in an intact animal. The weanling mouse
uterotropic assay, one ofthe mostwell-estab-
lished and widely used methods to detect
estrogenicity, was employed to determine if
exposure to the test chemical led to increased
uterinewetweight (7).
Thus, 10 chemicals were assessed for evi-
dence ofestrogenicity at three levels ofactivi-
ty. The results indicate that this combination
oftests may provide an efficient and effective
approach to screening environmental chemi-
cals forestrogenic activity.
Address correspondence to M.D. Shelby, National
Institute of Environmental Health Sciences, PO
Box 12233, MD A2-03, Research Triangle Park,
NC 27709 USA. V.L. Davis is now at the
Department of Comparative Medicine, Bowman
Gray School of Medicine, Winston-Salem, NC
27157-1040 USA.
A portion ofthe workpresented here was supported
by the Agency for Toxic Substances and Disease
Registry through Interagency Agreement 95-1032-
00. We gratefilly acknowledge the technical exper-
tise of Elizabeth Padilla-Burgos in performing the
uterotropic assays and the assistance ofWendy N.
Jefferson in the analysis and presentation ofdata.
Received 17 July 1996; accepted 16 September
1996.
Volume 104, Number 12, December 1996 * EnvironmentalHealth Perspectives 1296Articles * Three assays for estrogenicity
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Materials and Methods
Chemicals. The following chemicals were
obtained from Sigma Chemical Co. (St.
Louis, MO): diethylstilbestrol (DES; 99+%
pure); 17P-estradiol (E2; 99+% pure); and
tamoxifen (99% pure). 4-Hydroxytamoxifen
(99+% pure) was a gift from ICI Pharma-
ceuticals (Wilmington, DE). Other chemi-
cals were obtained as follows: methoxychlor
(98% pure) from Drexel Chemical Co.
(Memphis, TN); 2,2-bis(p-hydroxyphenyl)-
1,1,1-trichloroethane (HPTE; 99+% pure)
from Cedra Corp. (Austin, TX); a,b-endo-
sulfan (98% pure; a = 78%, b = 20%) and
kepone (98% pure) from Chem Service
(West Chester, PA); nonylphenol (99.5%
pure) from Schenectady International
(Schenectady, NY); and o,p'-DDT (99+%
pure) from Lancaster Synthesis (Windham,
NH). The structures of these chemicals are
presented in Figure 1.
cnmpetive biniga&say. [2,4,6,7-3H] E2,
110 Ci/mmol, with >98% radiochemical puri-
ty was obtained from Du Pont-New
England Nuclear (Boston, MA). The com-
petitive binding assay was carried out
according to the previously described pro-
cedure (8). Estrogen receptors were
obtained from female CD-1 [ICR] BR
mice from Charles River Breeding
Laboratories (Raleigh, NC). Females were
ovariectomized at 10-12 weeks ofage and
sacrificed 2 weeks later. Animals were kept
in a controlled environment with 12 hr of
light and 12 hr of dark. The autoclavable
NIH-31 open formula, natural ingredient
rodent diet (Agway, Inc., St. Mary, OH)
and reverse osmosis/deionized (RO/DI)
water were given adlibitum. After sacrifice
by cervical dislocation at 8-10 weeks of
age, the uteri were removed and frozen on
dry ice. The frozen uteri were then placed
in ice-cold TEGM buffer (10 mM Tris,
1.5 mM EDTA, 10% glycerol, 3 mM
MgCI2, pH 7.6) and homogenized with a
Polytron (Brinkmann Instruments,
Westbury, NY) for 15 sec at speed setting
6.5 at a ratio of 50:1 (milligrams of tissue
weight/per milliliter of buffer). The
homogenate was filtered through 100-125
mm mesh Nitex filtering media and cen-
trifuged at 1,000g for 10 min; the super-
natant was then decanted and centrifuged
at 45,000 rpm for 50 min. The 105,000g
supernatant was used for cytosol receptor
binding assays.
Aliquots of 100 pl cytosol were incu-
bated with 5 nM [3H]E2 and increasing
concentrations of unlabeled competitors
(0.5 nM-5 pM). The mixtures were incu-
bated at 40C for 18 hr, and then 250 pl of
60% HAP (hydroxyapatite) in TEGM
buffer was added to each tube. Tubes were
centrifuged at 1,000g for 10 min and the
resulting HAP pellet was washed twice
with 3 ml TEGM buffer then suspended in
scintillation cocktail. The radioactivity was
measured using a Beckman CS 9800 scin-
tillation counter (Beckman, Fullerton,
CA). The binding affinities were deter-
mined using Ligand Competition Analysis
Software by Lundon Software (Chagrin
Falls, OH).
Transcriptionalactivation assay in ER-
transfected HeLa cells. HeLa cells were
used because of their estrogen responsive-
ness in the presence of ER and estrogens,
allowing for detection ofweak estrogens. In
addition, they can be treated in serum-free
media to ensure that the estrogen back-
ground is null. Testing with and without
the ER proves that any response is through
direct interactions with the ER. The mouse
ER was used in these experiments for con-
sistency among the three assays.
The estrogen responsive reporter vec-
tor, ERET81CAT, and the pRSV vector
containing the mouse ER cDNA (without
the neomycin resistance cassette) was con-
structed as previously described (9). HeLa
cells, which do not contain ER, were
cotransfected with both vectors or with
only the ERET81CAT vector to determine
ifobserved activity was ER dependent. The
cells were grown in DMEM/F12 medium
(1:1) without phenol red (Sigma), supple-
mented with 5% fetal bovine serum and
penicillin-streptomycin. Cells were electro-
porated and treated as previously described
(6). During and after transfection, the cells
were maintained in DMEM/F12 medium
plus insulin-transferrin-sodium selenite
(Sigma). All procedures using serum-free
conditions were performed with Falcon
plastics (Becton Dickinson, Franklin Lakes,
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Figure 2. Competitive binding assay. Abbreviations: DES, diethylstilbestrol;
HPTE, 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane. Mouse uterine cytosol
was incubated with 5 nM of[3HJE2, and 0.5 nM-5 pM of unlabeled test chemi-
cals. After incubation for 18 hr at 4°C, the receptor was precipitated by addi-
tion of 60% hydroxyapatite. The precipitate was washed with buffer and the
radioactivity was counted as described in Materials and Methods. Results are
representative oftwo separate experiments performed in duplicate.
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Figure 3. Transfection assay. Abbreviations: DES, diethylstilbestrol; HPTE, 2-2-
bis(p-hydroxyphenyl)-1,1,1-trichloroethane. Dose curves represent estrogenic
activation of a CAT reporter gene in HeLa cellstransfected with the mouse estro-
gen receptor (mER). Fold induction of CAT protein levels was determined from
basal CAT levels (vehicle only) in HeLa cells transfected with the mouse ER
expression and ERET81CAT reporter vectors. The data representthe mean ± SE.
Dose curves were determined from at least three separate transfection experi-
ments.
Kepone 1,000 nM
o,p'-DDT 10,000
Nonylphenol 5,000 nM
Endosulfan 1,000 nM
HPTE 1,000 nM
Methoxychlor 1,000 nM
4-HydroxVtamoxifen 10 nM
Tamoxifen 1,000 nM
DES 1 nM
17i-Estradiol 1 nM
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Figure 4. Transfection assay. Abbreviations: HPTE, 2-2-bis(p-hydroxypher
diethylstilbestrol. Estrogen receptor (ER)-dependent activation of an estrc
gene. Fold induction of CAT protein levels was determined from basal CA
cellstransfected with the mouse ER expression and ERET81CAT reporter ve
reporter vector only (- ER). Cells were treated intriplicate and the data repr
NJ). Triplicate samples for each hormone
concentration were harvested at 28 hours
post-transfection and assayed for CAT pro-
0W isN 1211 tein using the CAT-ELISA kit (Boehringer
M +ER Mannheim, Indianapolis, IN) according to
the manufacturer's instructions.
Mouse uterotropic bioassay. Female
CD-1 mice [Crl:CD-1(ICR)] (Charles
River Breeding Laboratories) were bred to
males of the same strain at NIEHS. Timed
pregnant females delivered their young on
day 19 of gestation. At delivery, all litters
were randomly standardized to 10 female
pups per dam. All animals were housed in a
temperature-controlled room (22 ± C)
with a 12 hr light and 12 hr dark cycle.
Mice were provided with RO/DI water and
fed autoclavable NIH-31 rodent diet ad
libitum. All animal care procedures were
preapproved by the NIEHS Animal Care
and Use Committee and complied with the
procedures in the Guide for the Care and
Use ofLaboratory Animals. Female pups
were weaned on day 17 and housed five per
30 35 40 45 cage. Starting on day 17, the immature
mice were subcutaneously injected for 3
yl)-1,1,1-trichloroethane; DES, consecutive days withvarying doses ofeach
ogen-responsive CAT reporter test compound dissolved in corn oil and
LT levels (vehicle only) in HeLa were sacrificed on the morning of the
ectors (+ ER) orthe ERET81CAT fourth day (20 days old). High doses were
*esentthe mean ± SE. selected based on a maximum of 1,000,000
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Figure 5. Uterotropic assay. Abbreviations: DES, diethylstilbestrol; HPI
trichloroethane. Immature CD-1 mice were treated subcutaneouslywith
cals dissolved in corn oil on postnatal days 17, 18, and 19. Animals wer
day following the last injection (day 20). A ratio of uterine weights to bc
are the mean ±the SE. Each data point represents results from a minimL
Table 1. Summary of estrogenicity test results
Competitive Transcriptional Uterotropic
Chemical binding activation assay Comments
17P-Estradiol +++ +++ +++ Positive con
DES +++ +++ +++ Positive con
Tamoxifen ++ ++ ++ Intrinsic est
4-Hydroxytamoxifen ++ ++ ++ Metabolite
Methoxychlor - - ++ Requires me
HPTE ++ ++ ++ Estrogenicr
Endosulfan - - - No evidencE
p-Nonylphenol + ++ + Confirms int
o,p'-DDT + + + Confirms int
Kepone - - + Weak in viv
Abbreviations: DES, diethylstilbestrol; HPTE, 2,2-bis(p-hydroxyphenyl)-1,
+ = Positive test results; relative levels ofeffects are indicated by numb(
pg/kg or mortality in range-finding studies.
No deaths were observed in any of the
high-dose groups reported here. Body
weights and uterine wet weights were
determined. Uterine tissues were fixed in
Bouin's fixative and processed for future
histological examination. A minimum of
five mice per dose point were used.
Results and Discussion
Results ofthe competitive binding (Fig. 2),
transcriptional activation (Fig. 3,4), and
uterotropic as
and DES wer
current stud)
performance
vide reference
pare the resu
cals. Both pr
exhibiting su
activity in all
other eight ch
The breas
agent tamox
MANOMM" hydroxytamoxifen, exhibit both estrogenic
_ o _ 1 1 11_1| and antiestrogenic activities (10,11).
A 17V-Estradiol Tamoxifen and 4-hydroxytamoxifen both
V TamofES n exhibited potent dose-related effects in all
* Tmoien_;A * 4-Hydroxytamoxifen three assays. While these two chemicals 2 Methoxychlor gave nearly identical effects in the A HPTE C Endosulfan uterotropic assay (Fig. 5), the metabolite
V Nonylphenol consistentlyexhibited greater activity in the O o,p'-D1T O Kepone transfection assay (Fig. 3) and the receptor
binding assay (Fig. 2), which do not
employ an exogenous source of metabolic
activation. These results show the inherent
estrogenic activity of tamoxifen and
demonstrate that this activity is enhanced
byhydroxylation.
Evidence ofthe in vivo estrogenic activ-
ity ofmethoxychlor and its requirement for
metabolic conversion to HPTE, the active
estrogen, is reviewed by Bulger and Kupfer
(12,13). In contrast to tamoxifen,
methoxychlor exhibits no intrinsic estro-
genic activity, and conversion to HPTE is
required for activity. No activity was seen
with methoxychlor in either in vitro assay,
whereas HPTE was clearly active in both
assays (Fig. 2,3). In contrast, methoxychlor
induced large increases in uterine weights
...0.0 O at high doses and, although HPTE was
active in the same dose range, it produced
much smaller increases in uterine weights
TE, 2-2-bis(p-hydroxyphenyl)-1,1,1- (Fig. 5). These results suggest that subcuta-
hvarious concentrations ofchemi- neous exposure to HPTE results in lower
e sacrificed on the morning ofthe target organ concentrations than does equal
dy weights was plotted. Numbers exposure to the parent compound. This
um offive animals.
may be due to greater reactivity of the
active metabolite and more rapid inactiva-
tion or detoxification.
o,p'-DDT and nonylphenol are envi-
ronmental contaminants with reported
itrol estrogenic activity (14-19). Both exhibited
trol estrogenicity in the three assays reported
rogenic activfty here. In the competitive binding assay (Fig.
shows greateractivity in vitro 2), nonylphenol reduced estradiol binding ttabolic activation v v
metabolite ofmethoxychlor by about 20% at the highest concentration
e ofestrogenicityinthesethreetests tested. In the transfection assay (Fig. 3),
rinsic and in vivoestrogenicactivity transcription was induced by nonylphenol
rinsic and invivoestrogenic activity to a level greater than tamoxifen or 4-
oeffect hydroxytamoxifen and equal to HPTE. An
JJ ,-trichloroethane. effect was also seen in the uterotropic assay,
er of+s. -= Negative test results. albeit at doses exceeding 10,000 pg/kg.
These results extend the characterization of
nonylphenol's estrogenic activity as report-
;says (Fig. 5) are presented. E2 ed by Soto et al. (17) using MCF7 cells
*e included as standards in the and Lech et al. (19) using vitellogenin
y to monitor and assure the mRNA induction in trout liver.
ofthe test systems and to pro- Over the same dose range where effects
e data against which to com- were seen with nonylphenol, o,p'-DDT
Its of the other eight chemi- gave a greater response in the receptor bind-
*oduced the effects expected, ing assay (Fig. 2). Although o,p'-DDT gave
Lbstantially greater estrogenic a response in the transfection assay (Fig. 3),
three assays than any of the it was less active than nonylphenol. o,p'-
iemicals. DDT was uterotropic (Fig. 5), showing
,t cancer adjuvant therapeutic roughly the same level ofeffect in the same
ifen and its metabolite, 4- dose range as HPTE and nonylphenol.
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In the present studies, the reported
estrogenic chemicals endosulfan (20) and
kepone (13,21-24) were both negative in
the receptor binding assay (Fig. 2) and the
transcriptional activation assay (Fig. 3),
indicating no activity in vitro. These
kepone results are in contrast to reports of
binding to the estrogen receptors of ani-
mals other than mice. Consistent with
these negative results in vitro, endosulfan
was negative in the uterotropic assay (Fig.
5). However, kepone gave a small dose-
related increase in uterine weights over a
dose range of 100-10,000 pg/kg (Fig. 5).
This result agrees with earlier reports of
similar effects in birds and rats (13) and
mice (24). In the uterotropic assay, test
doses for both endosulfan and kepone were
limited to 10,000 pg/kg by toxicity.
Further studies on the estrogenic potential
ofthese two chemicals are underway.
As seen in Table 1, results were the
same in the two in vitro assays for all 10
chemicals. Because these two assays mea-
sure different endpoints, they should not,
at this time, be considered redundant.
Testing of a larger, more diverse set of
chemicals may reveal differences in
responses. This is likely to occur with estro-
gen antagonists that bind the receptor but
do not activate transcription. Further, the
lack of an exogenous source of metabolic
activation is a current limitation to the in
vitro assays, for which there is only partial
compensation by the use ofthe uterotropic
assays in the three-test combination.
Finally, in reaching judgments on the
biological significance or hazard associated
with estrogenic activity identified in tests
such as those reported here, it is important
to keep in mind that the activity of some
chemicals is observed only at levels ofexpo-
sure that are orders of magnitude higher
than those where effects are seen with
estrogens such as estradiol and DES.
In summary, the combination of three
assays employed in this study provides a
rational and informative approach to assess-
ing the estrogenicity of chemicals.
Consistency ofresults among all three assays,
as seen with the tamoxifens, HPTE, and
o,p'-DDT, offers assurance that the chemical
under study is truly estrogenic or, with con-
sistent negative results as with endosulfan,
lacks meaningful estrogenic activity.
Inconsistent results may also be informative,
providing clues as to mechanism ofaction of
the testchemical, e.g., binding to the ERand
failure to elicit transcription or uterotropic
responses would suggest that a chemical
inactivates the receptor. Activity in both the
receptor binding and transcriptional activa-
tion tests and negative results in the
uterotropic assay would suggest inactivation
ofthe chemical in vivoorfailure to distribute
to the uterus. Likewise, failure to bind to the
ER or induce transcription while leading to
uterotrophy, as was seen with methoxychlor,
indicates the requirement for metabolic acti-
vation or a mechanism independent of the
estrogen receptor.
This three-test combination offers a
systematic and mechanistically informative
approach to assessing estrogenicity. It pro-
vides a useful profile ofactivity using a rea-
sonable amount of resources and is com-
patible with the study ofindividual chemi-
cals as well as the investigation of interac-
tions among combinations of chemicals.
Such an approach is needed ifthe presence
of estrogenic agents in the environment is
to be determined as a first step toward
assessing the health hazards they may pre-
sent to humans and other forms oflife.
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